Ultragenyx Pharmaceutical (RARE) Interest Coverage Ratio (2013 - 2026)
Ultragenyx Pharmaceutical's (RARE) quarterly Interest Coverage Ratio came in at 8.05 in Q1 2026, up 21.21% year-on-year from 6.64 in Q1 2025, and down 38.31% on a QoQ basis from 5.82 in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Interest Coverage Ratio (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has 14 years of Interest Coverage Ratio data on file, last reported at 8.05 in Q1 2026.
- On a quarterly basis, Interest Coverage Ratio rose 21.21% year-over-year to 8.05 in Q1 2026; TTM through Mar 2026 was 8.17, a 2.71% increase from a year earlier, with the FY2025 full-year figure at 8.63, down 1.42% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 8.05, down from 5.82 in the prior quarter.
- Over the last five years, Interest Coverage Ratio for RARE reached as high as 5.82 in Q4 2025 and fell as low as 20.75 in Q1 2022.
- Historically, Interest Coverage Ratio has averaged 10.33 across 5 years, with a median of 9.17 in 2022.
- On a YoY basis, Interest Coverage Ratio climbed as much as 65.97% in 2022 and fell as far as 81.25% in 2022.
- Year by year, Interest Coverage Ratio stood at 9.17 in 2022, then rose by 23.34% to 7.03 in 2023, then fell by 12.33% to 7.9 in 2024, then climbed by 26.35% to 5.82 in 2025, then sank by 38.31% to 8.05 in 2026.
- Per Business Quant data, the three most recent Interest Coverage Ratio figures were 8.05 in Q1 2026, 5.82 in Q4 2025, and 12.08 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Ultragenyx Pharmaceutical | 2.72 Bn | 2.31 Bn | 106.00 Mn | -8.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.05 |
| Dec 31, 2025 | -5.82 |
| Sep 30, 2025 | -12.08 |
| Jun 30, 2025 | -7.68 |
| Mar 31, 2025 | -10.21 |
| Dec 31, 2024 | -7.90 |
| Sep 30, 2024 | -8.40 |
| Jun 30, 2024 | -7.29 |
| Mar 31, 2024 | -10.43 |
| Dec 31, 2023 | -7.03 |
| Sep 30, 2023 | -8.21 |
| Jun 30, 2023 | -9.62 |
| Mar 31, 2023 | -9.86 |
| Dec 31, 2022 | -9.17 |
| Sep 30, 2022 | -15.52 |
| Jun 30, 2022 | -17.62 |
| Mar 31, 2022 | -20.75 |
| Dec 31, 2021 | -26.96 |
| Sep 30, 2021 | -10.35 |
| Jun 30, 2021 | -9.72 |